<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRIM11 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TRIM11</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TRIM11</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=TRIM11" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a>, <a href="/wiki/tauopathies" style="color:#ef9a9a">Tauopathies</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>
TRIM11 (Tripartite Motif Containing 11) is a member of the tripartite motif (TRIM) family of E3 ubiquitin ligases with significant roles in regulating protein quality control, [neuronal survival](/entities/neurons), and the pathogenesis of neurodegenerative diseases. Located on chromosome 1q42.13, TRIM11 is predominantly expressed in the brain, with high expression in the [cerebral cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [cerebellum](/brain-regions/cerebellum), and [striatum](/brain-regions/striatum)[@ncbi].
TRIM11 has emerged as a critical regulator of [Alzheimer's disease](/diseases/alzheimers-disease) pathology through its ability to degrade misfolded proteins, including amyloid-beta (Abeta) aggregates and tau oligomers. The protein also plays important roles in [prion disease](/diseases/prion-diseases) and has been implicated in [Parkinson's disease](/diseases/parkinsons-disease) through its interactions with alpha-synuclein["@hatakeyama2017"]. The therapeutic potential of TRIM11 as a modulator of protein aggregation in neurodegenerative diseases has attracted significant research interest.
The TRIM11 gene encodes a protein of approximately 462 amino acids with a molecular weight of approximately 52 kDa. Like other TRIM family members, TRIM11 possesses the characteristic tripartite motif architecture: an N-terminal RING finger domain (C3HC4 type) that confers E3 ubiquitin ligase activity, followed by one or two B-box domains that mediate substrate recognition, and a C-terminal coiled-coil region that facilitates protein dimerization[@meroni2005].
The RING domain of TRIM11 contains the catalytic cysteine and histidine residues required for zinc coordination and E3 ligase function. This domain facilitates the transfer of ubiquitin from E2 conjugating enzymes to lysine residues on target proteins, marking them for proteasomal degradation or altering their function through non-degradative ubiquitination. The B-box domains serve as substrate recognition modules, enabling TRIM11 to specifically interact with disease-associated proteins. The coiled-coil region mediates homodimerization, which is essential for E3 ligase activity.
TRIM11 shares structural homology with other brain-expressed TRIM proteins, including TRIM9, TRIM17, and TRIM32, suggesting conserved functions in neuronal protein quality control. However, TRIM11 has evolved specialized functions in the degradation of aggregation-prone proteins, particularly those implicated in AD and prion diseases.
TRIM11 functions as an E3 ubiquitin ligase, catalyzing the covalent attachment of ubiquitin to target proteins. The ubiquitin-proteasome system (UPS) is the primary cellular pathway for targeted protein degradation, and TRIM11 plays a key role in recognizing and tagging misfolded or aggregation-prone proteins for proteasomal clearance[@chen2019].
TRIM11-mediated ubiquitination can result in different outcomes depending on the substrate and ubiquitin chain type. Monoubiquitination often serves signaling functions, while polyubiquitination with K48-linked chains typically targets proteins for proteasomal degradation. TRIM11 can also generate K63-linked ubiquitin chains that serve non-degradative functions, including signaling and autophagy regulation.
One of the most significant functions of TRIM11 in the context of Alzheimer's disease is its role in regulating amyloid-beta (Aβ) metabolism. TRIM11 has been shown to directly interact with Aβ aggregates and promote their ubiquitination and subsequent degradation by the [26S proteasome](/proteins/26s-proteasome)[@yang2018].
In cellular and animal models of AD, TRIM11 overexpression reduces intracellular Aβ accumulation and extracellular plaque formation, while TRIM11 knockdown increases Aβ toxicity. These effects are mediated through TRIM11's E3 ligase activity, as mutants lacking the RING domain fail to clear Aβ. TRIM11 can also regulate the amyloid precursor protein (APP) processing pathway, influencing the generation of Aβ peptides from APP.
TRIM11 also plays important roles in regulating tau pathology in Alzheimer's disease. Tau protein aggregation into neurofibrillary tangles is a hallmark of AD, and TRIM11 has been shown to promote the degradation of hyperphosphorylated tau and tau oligomers[@zhang2019].
TRIM11 interacts with tau kinases and phosphatases, potentially modulating the phosphorylation state of tau. Additionally, TRIM11 can ubiquitinate aggregated tau species, targeting them for proteasomal clearance. The regulation of tau homeostasis by TRIM11 is particularly important given the strong correlation between tau pathology and cognitive decline in AD.
In prion diseases, TRIM11 has been shown to regulate the aggregation and toxicity of misfolded prion protein (PrPSc). TRIM11 can ubiquitinate prion protein aggregates and promote their degradation, potentially representing a cellular defense mechanism against prion toxicity[@yan2019].
The role of TRIM11 in prion disease is particularly interesting given the mechanistic similarities between prion aggregation and other neurodegenerative proteinopathies. Understanding how TRIM11 recognizes and clears prion aggregates may inform therapeutic strategies for multiple protein aggregation disorders.
TRIM11 has been implicated in [Parkinson's disease](/diseases/parkinsons-disease) through its interactions with alpha-synuclein, the protein that forms Lewy bodies in PD [neurons](/entities/neurons). TRIM11 can ubiquitinate alpha-synuclein and promote its degradation through both proteasomal and autophagic pathways[@kim2018].
However, the role of TRIM11 in PD is complex, as alpha-synuclein aggregation can overwhelm cellular quality control mechanisms, including those mediated by TRIM11. The balance between TRIM11 activity and alpha-synuclein burden may influence disease progression.
TRIM11 regulates [apoptosis](/entities/apoptosis) in [neurons](/entities/neurons) through its interactions with key apoptotic regulators. TRIM11 can modulate both the intrinsic (mitochondrial) and extrinsic (death receptor) pathways of apoptosis, influencing neuronal survival under conditions of cellular stress[@chen2019].
TRIM11 can interact with p53, a central regulator of apoptosis, and modulate its stability and transcriptional activity. Additionally, TRIM11 can regulate the levels of pro-apoptotic and anti-apoptotic proteins, including Bcl-2 family members, influencing the threshold for apoptotic activation in neurons.
TRIM11 exhibits high expression in the brain, with particular enrichment in the [cerebral cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [cerebellum](/brain-regions/cerebellum), [striatum](/brain-regions/striatum), and [substantia nigra](/brain-regions/substantia-nigra). Within these regions, TRIM11 is expressed primarily in [neurons](/entities/neurons), with lower expression in glial cells.
At the subcellular level, TRIM11 localizes to the [cytoplasm](/entities/cytoplasm), with enrichment in the [endoplasmic reticulum](/entities/endoplasmic-reticulum) and in proximity to the [aggresome](/entities/aggresome). This localization pattern is consistent with TRIM11's role in protein quality control and its interactions with aggregation-prone proteins.
TRIM11 can also be found in the nucleus, where it may regulate the degradation of nuclear proteins and influence gene expression. The shuttling of TRIM11 between cellular compartments may be regulated by cellular stress and protein aggregation burden.
TRIM11 has strong associations with Alzheimer's disease through multiple mechanisms. The protein plays crucial roles in clearing amyloid-beta and tau, two hallmark pathologies of AD. TRIM11 expression is altered in AD brain tissue, with some studies showing decreased levels that may contribute to the accumulation of toxic protein aggregates.
Therapeutic strategies aimed at enhancing TRIM11 function could potentially reduce Aβ and tau pathology in AD. However, the complexity of TRIM11 function requires careful consideration of potential off-target effects.
TRIM11 is implicated in prion diseases, where it may serve as a cellular defense mechanism against prion protein aggregation. The protein's ability to recognize and ubiquitinate misfolded prion protein suggests potential therapeutic applications for prion disorders, which remain uniformly fatal.
Through its regulation of alpha-synuclein metabolism, TRIM11 has connections to Parkinson's disease. While not a primary causal gene, TRIM11 may modulate the progression of alpha-synuclein pathology in PD.
TRIM11 has been implicated in other neurodegenerative conditions, including Huntington's disease and frontotemporal dementia, through its general functions in protein quality control and apoptosis regulation.
TRIM11 represents a promising therapeutic target for neurodegenerative diseases characterized by protein aggregation. Several strategies could be developed:
Protein Quality Control Enhancement: Compounds that enhance TRIM11 expression or activity could boost the cell's capacity to clear toxic protein aggregates. Small molecules that activate TRIM11's E3 ligase activity could be particularly valuable.
Gene Therapy: Viral vector-mediated delivery of TRIM11 to affected brain regions could provide sustained therapeutic benefit. AAV vectors targeting neurons could achieve specific expression in relevant cell types.
Protein-Protein Interaction Modulators: Compounds that enhance TRIM11's interactions with specific disease proteins (Aβ, tau, alpha-synuclein, prion protein) could improve aggregate clearance.
Combination Approaches: Combining TRIM11 enhancement with other therapeutic strategies, such as amyloid-targeted antibodies or tau-targeted approaches, may provide synergistic benefits.
Several key questions remain regarding TRIM11 biology and therapeutic targeting:
The following diagram shows the key molecular relationships involving TRIM11 Gene discovered through SciDEX knowledge graph analysis: